Keytruda’s liver cancer approval secured by new studyMerck & Co’s FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial Share XKeytruda’s liver cancer approval secured by new studyhttps://pharmaphorum.com/news/keytrudas-liver-cancer-approval-secured-by-new-study/
PROpel study backs Lynparza combo in first-line prostate cancerAstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a Share XPROpel study backs Lynparza combo in first-line prostate cancerhttps://pharmaphorum.com/news/propel-study-backs-lynparza-combo-in-first-line-prostate-cancer/
Boehringer buys Abexxa, bolstering its immuno-oncology pipelineBoehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area Share XBoehringer buys Abexxa, bolstering its immuno-oncology pipelinehttps://pharmaphorum.com/news/boehringer-buys-abexxa-bolstering-its-immuno-oncology-pipeline/
FDA clears Seagen, Genmab’s Tivdak ADC for cervical cancerAntibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from Share XFDA clears Seagen, Genmab’s Tivdak ADC for cervical cancerhttps://pharmaphorum.com/news/fda-clears-seagen-genmabs-tivdak-adc-for-cervical-cancer/
ESMO21: Libtayo extends survival in first-line NSCLC, challenging KeytrudaThere’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the Share XESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytrudahttps://pharmaphorum.com/news/esmo21-libtayo-extends-survival-in-first-line-nsclc-challenging-keytruda/
ESMO21: Enhertu brings it’s A game to second-line breast cancerAstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Share XESMO21: Enhertu brings it’s A game to second-line breast cancerhttps://pharmaphorum.com/news/esmo21-enhertu-brings-its-a-game-to-second-line-breast-cancer/
ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDsRoche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective Share XESMO21: Roche’s giredestrant takes stage in battle of the oral SERDshttps://pharmaphorum.com/news/esmo21-roches-giredestrant-takes-stage-in-battle-of-the-oral-serds/
ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRCAmgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting Share XESMO21: First combo data with Amgen’s Lumakras hit the mark in CRChttps://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/
First FDA filing for Novartis’ latecomer PD-1 drug tislelizumabNovartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier Share XFirst FDA filing for Novartis’ latecomer PD-1 drug tislelizumabhttps://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/
